Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Liabilities and Shareholders Equity: 2018-2019

Historic Liabilities and Shareholders Equity for DiaMedica Therapeutics (DMAC) over the last 1 years, with Sep 2019 value amounting to $11.0 million.

  • DiaMedica Therapeutics' Liabilities and Shareholders Equity was N/A to $11.0 million in Q3 2019 from the same period last year, while for Sep 2019 it was $57.7 million, marking a year-over-year change of. This contributed to the annual value of $18.3 million for FY2018, which is N/A change from last year.
  • As of Q3 2019, DiaMedica Therapeutics' Liabilities and Shareholders Equity stood at $11.0 million, which was down 13.74% from $12.8 million recorded in Q2 2019.
  • DiaMedica Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $18.3 million during Q4 2018, with a 5-year trough of $11.0 million in Q3 2019.
  • Its 2-year average for Liabilities and Shareholders Equity is $14.4 million, with a median of $14.1 million in 2019.